임상 레이더 AI | ||
|---|---|---|
임상시험 NCT07334860은(는) 건강한에 대해 진행중, 모집종료 상태입니다. 모든 세부 정보를 보려면 임상시험 레이더 카드 뷰와 AI 발견 도구를 확인하거나 여기에서 무엇이든 물어보세요. | ||
하나의 임상시험이 필터 기준과 일치합니다.
카드 뷰
검색으로 돌아가기
머크A Clinical Trial to Compare Forms of MK-1167 in Healthy People (MK-1167-011) 1상 16
임상시험 세부 정보는 주로 영어로 제공됩니다. 하지만 임상 레이더 AI가 도와드릴 수 있습니다! '임상시험 설명'를 클릭하여 선택한 언어로 임상시험 정보를 확인하고, 이에 대해 AI와 논의해 보세요.
임상시험 NCT07334860은(는) 기초과학을(를) 알아보기 위한 연구입니다. 이 연구는 건강한에 대해 진행되며, 1상 중재연구으로 현재 상태는 진행중, 모집종료입니다. 연구는 2026년 2월 6일에 시작되어 16명의 참여자를 모집하고 있습니다. 머크이(가) 진행하며, 2026년 5월 28일까지 완료될 예정입니다. ClinicalTrials.gov의 가장 최근 정보는 2026년 3월 19일에 갱신되었습니다.
간단한 개요
Researchers are looking for new ways to treat Alzheimer's disease (AD). AD is a brain disease that causes a gradual decline in memory, thinking, and ability to carry out daily tasks. MK-1167 is a study medicine designed to treat symptoms of AD. Before giving a study medicine to people with a health condition, researchers first do studies in healthy people to find a safe dose of the study medicine.
The goals of the t...
더 보기공식 제목
A Two-Period, Open-label, Fixed-Sequence Study to Evaluate the Single-Dose Pharmacokinetics of Two Formulations of MK-1167 in Healthy Participants
질환명
건강한기타 연구 식별자
- 1167-011
- MK-1167-011 (기타 식별자) (MSD)
NCT 번호
실제 연구 시작일
2026-02-06
최신 업데이트 게시
2026-03-19
예상 연구 완료일
2026-05-28
계획된 등록 인원
16
연구종류
중재연구
단계/상
1상
상태
진행중, 모집종료
주요 목적
기초과학
설계 할당
비랜덤화 배정
중재 모델
순차설계
맹검 (마스킹)
없음 (오픈 라벨)
시험군 / 개입
| 참가자 그룹/시험군 | 개입/치료 |
|---|---|
실험적Arm 1: MK-1167 Form 2 Participants receive MK-1167 Form 2 orally. | MK-1167 Oral administration |
실험적Arm 2: MK-1167 Form 1 Participants receive MK-1167 Form 1 orally. | MK-1167 Oral administration |
주요결과변수
이차결과변수
| 결과변수 | 측정값 설명 | 시간 범위 |
|---|---|---|
Area Under the Curve from Time 0 to Infinity (AUC0-inf) of MK-1167 | Blood samples will be collected to determine the AUC0-inf of MK-1167. | At designated time points (up to approximately 21 days) |
Maximum Plasma Concentration (Cmax) of MK-1167 | Blood samples will be collected to determine the Cmax of MK-1167. | At designated time points (up to approximately 21 days) |
Area Under the Curve from Time 0 to Last Measurable Concentration (AUC0-last) of MK-1167 | Blood samples will be collected to determine the AUC0-last of MK-1167. | At designated time points (up to approximately 21 days) |
| 결과변수 | 측정값 설명 | 시간 범위 |
|---|---|---|
Area Under the Curve from Time 0 to 24 hours (AUC0-24) of MK-1167 | Blood samples will be collected to determine the AUC0-24 of MK-1167. | At designated time points (up to approximately 24 hours) |
Concentration at 24 hours (C24) of MK-1167 | Blood samples will be collected to determine the C24 of MK-1167. | At designated time points (up to approximately 24 hours) |
Time to Maximum Serum Concentration (Tmax) of MK-1167 | Blood samples will be collected to determine the Tmax of MK-1167. | At designated time points (up to approximately 21 days) |
Apparent Terminal Half-life (t1/2) of MK-1167 | Blood samples will be collected to determine the t1/2 of MK-1167. | At designated time points (up to approximately 21 days) |
Apparent Clearance after Nonintravenous Administration (CL/F) of MK-1167 | Blood samples will be collected to determine the CL/F of MK-1167. | At designated time points (up to approximately 21 days) |
Apparent Volume of Distribution during Terminal Phase (Vz/F) of MK-1167 | Blood samples will be collected to determine the Vz/F of MK-1167. | At designated time points (up to approximately 21 days) |
Number of Participants Who Experience One or More Adverse Events (AEs) | An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experience an AE will be reported. | Up to approximately 78 days |
Number of Participants Who Discontinue Study Intervention Due to an AE | An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who discontinue study treatment due to an AE will be reported. | Up to approximately 36 days |
참여 도우미
적격성 기준
연령대
성인
최소 연령
18 Years
참여 가능한 성별
전체
건강한 참가자 허용
네
- Is in good health
- Has a body mass index (BMI) ≥18 and ≤ 32 kg/m^2, inclusive
- Has a history of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological abnormalities or diseases
- Is a smoker and/or has used nicotine or nicotine-containing products within the past 3 months.
머크연락처 정보가 없습니다.
1 1개국에 임상시험 장소
Florida
QPS-MRA, LLC ( Site 0001), South Miami, Florida, 33143, United States